Видео ютуба по тегу Magnetismm-3

MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma
MagnetisMM-3: Long Term Efficacy & Safety of Less Frequent Elranatamab Dosing R/R Multiple Myeloma
Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD | #ASH25 #myeloma
MagnetisMM‑3: Pausing Elranatamab Without Losing Response | Alexander Lesokhin, MD | #ASH25 #myeloma
Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022
Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022
MagnetisMM-3: elranatamab for myeloma
MagnetisMM-3: elranatamab for myeloma
Subgroup analysis of MagnetisMM-3: less frequent dosing of elranatamab for multiple myeloma
Subgroup analysis of MagnetisMM-3: less frequent dosing of elranatamab for multiple myeloma
EHA 2023 | MagnetisMM 3 clinical trial
EHA 2023 | MagnetisMM 3 clinical trial
MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections
MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections
MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy
MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy
Patient-reported outcomes with the use of elranatamab in the MagnetisMM-3 trial
Patient-reported outcomes with the use of elranatamab in the MagnetisMM-3 trial
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study | ASCO 2023
Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study | ASCO 2023
MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma
MagnetisMM-3: elranatamab in relapsed/refractory multiple myeloma
Elranatamab for R/R myeloma: long-term updates from MagnetisMM-3 & real-world safety of this agent
Elranatamab for R/R myeloma: long-term updates from MagnetisMM-3 & real-world safety of this agent
Ongoing studies of elranatamab in frail patients & with DaraPomDex: MagnetisMM-3 & MagnetisMM-5
Ongoing studies of elranatamab in frail patients & with DaraPomDex: MagnetisMM-3 & MagnetisMM-5
MagnetisMM-3 extended follow up results: elranatamab monotherapy in R/R multiple myeloma
MagnetisMM-3 extended follow up results: elranatamab monotherapy in R/R multiple myeloma
Elranatamab in Combination with Daratumumab for Pts with RRMM: Phase 3 MagnetisMM-5
Elranatamab in Combination with Daratumumab for Pts with RRMM: Phase 3 MagnetisMM-5
MagnetisMM-3: update on efficacy and safety of less frequent dosing of elranatamab in R/R myeloma
MagnetisMM-3: update on efficacy and safety of less frequent dosing of elranatamab in R/R myeloma
What Does MagentisMM-3 Data Tell Us About Elranatamab?
What Does MagentisMM-3 Data Tell Us About Elranatamab?